Home › Linfoma › Pennsylvania › Philadelphia
Studi clinici su Linfoma a Philadelphia, PA
15 studi su Linfoma cercano partecipanti presso sedi a Philadelphia e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
In reclutamentoStudio osservazionale
- Children's Hospital of Philadelphia, Philadelphia
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
In reclutamentoFase 1
- University of Pennsylvania - Abramson Cancer Center, Philadelphia
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
In reclutamentoFase 2
- University of Pennsylvania, Philadelphia
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
In reclutamentoFase 1/2
- Children's Hospital of Philadelphia-Center for Childhood Cancer Research, Philadelphia
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
In reclutamentoFase 1
- The Children's Hospital of Philadelphia (CHOP), Philadelphia
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
In reclutamentoFase 1/2
- Research Site, Philadelphia
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
In reclutamentoFase 1/2
- Children's Hospital of Philadelphia, Philadelphia
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
In reclutamentoFase 1
- Thomas Jefferson University, Philadelphia
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
In reclutamentoFase 1
- Hospital of the University of Pennsylvania, Philadelphia
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
In reclutamentoFase 1/2
- Thomas Jefferson University, Philadelphia
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
In reclutamentoFase 1/2
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
In reclutamentoFase 1
- Children's Hospital of Philadelphia, Philadelphia
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
In reclutamentoFase 1
- University of Pennsylvania, Abramson Cancer Center, Philadelphia
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
In reclutamentoStudio osservazionale
- Saint Christopher's Hospital for Children, Philadelphia
CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)
In reclutamentoFase 1
- University of Pennsylvania - Abramson Caner Center, Philadelphia
Studi su Linfoma in altre città
- Houston, TX34 studi
- Boston, MA33 studi
- New York City, NY33 studi
- Washington, DC23 studi
- Baldwin Park, CA21 studi
- Chicago, IL20 studi
- Durham, NC17 studi
- St. Louis, MO15 studi
- Cleveland, OH14 studi
- Edison, NJ12 studi
- Atlanta, GA12 studi
- Seattle, WA12 studi
Altri studi a Philadelphia
- Cancro (tutti i tipi)59 studi
- Cancro al seno56 studi
- Cancro del polmone non a piccole cellule51 studi
- Cancro metastatico46 studi
- Cancro colorettale44 studi
- Cancro ovarico44 studi
- Cancro alla prostata44 studi
- Cancro ai polmoni36 studi
- Leucemia mieloide acuta34 studi
- Insufficienza cardiaca31 studi
- Cancro dell'endometrio28 studi
- Depressione26 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.